Relmada Therapeutics (RLMD) Tops Q1 EPS by 3c

Relmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($0.87), $0.03 better than the analyst estimate of ($0.90).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• AXIL Brands (AXIL) Tops Q4 EPS by 4c